Results 161 to 168 of about 1,869 (168)

Lebrikizumab - nová možnost léčby atopické dermatitidy

Atopic dermatitis (AD) is a chronic inflammatory skin disease that primarily affects children and often persists into adulthood. Its etiology is multifactorial, with a significant role played by genetic predisposition, impaired skin barrier function, and dysregulation of the immune system, particularly Th2 response.
openaire   +1 more source

Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply.

The New England journal of medicine, 2023
Jonathan I, Silverberg, Emma, Guttman-Yassky, Renata, Gontijo Lima   +2 more
openaire   +1 more source

Lebrikizumab Decreases Type 2 Inflammatory Biomarker Levels in Patients With Asthma: Data From Randomized Phase 3 Trials (LAVOLTA I and II)

Immunotherapy
Jonathan Corren, Angela J Okragly, Jonathan Silverberg   +2 more
exaly  

Meta-Analysis of Randomized Controlled Trials for the Efficacy and Safety of Anti‐Interleukin-13 Therapy With Lebrikizumab in Patients With Uncontrolled Asthma

Allergy and Asthma Proceedings, 2018
exaly  

Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan

Dermatitis
Sei-ichiro Motegi, Hidehisa Saeki, Akihiko Uchiyama   +2 more
exaly  

Lebrikizumab‐induced head and neck dermatitis and conjunctivitis: a case report

JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Guillermo Pérez Limousin, Mónica Munera‐Campos, José Manuel Carrascosa   +2 more
openaire   +2 more sources

Use of Lebrikizumab in Treatment‐Refractory Bullous Pemphigoid: Two Reports

International Journal of Dermatology
Christoph Zeyen, Farzan Solimani, Meslina Almaci, Kamran Ghoreschi, Rose K. C. Moritz, Margitta Worm   +5 more
openaire   +2 more sources

Lebrikizumab - die personalisierte Asthmatherapie scheint möglich

Österreichische Apothekerzeitung, 2011
openaire   +1 more source